C4 Therapeutics (NASDAQ: CCCC) director receives grant of 62,000 stock options

Rhea-AI Filing Summary

C4 Therapeutics, Inc. director Utpal Koppikar received a grant of stock options to buy 62,000 shares of common stock. The options have an exercise price of $4.25 per share and expire on June 23, 2036.

The option award will vest and become exercisable in full on the earlier of June 24, 2027 or the company’s next annual stockholder meeting, as long as he continues serving on the Board through that date. Following this grant, he holds options covering 62,000 shares directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Koppikar Utpal

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	62,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 62,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 62,000 options Exercise price: $4.25 per share Shares underlying options: 62,000 shares +3 more

6 metrics

Option grant size 62,000 options Stock Option (Right to Buy) awarded to director

Exercise price $4.25 per share Conversion or exercise price of options

Shares underlying options 62,000 shares Underlying C4 Therapeutics common stock

Total options after grant 62,000 options Total derivative holdings following transaction

Option expiration June 23, 2036 Expiration date of stock options

Vesting date trigger June 24, 2027 Latest vesting date or earlier next annual meeting

Key Terms

Stock Option (Right to Buy), exercise price, expiration date, vest and become exercisable, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

exercise price financial

"conversion_or_exercise_price: "4.2500""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: "2036-06-23T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vest and become exercisable financial

"This option shall vest and become exercisable in full upon the earlier"

annual meeting of the Issuer's stockholders financial

"the next annual meeting of the Issuer's stockholders, subject to the recipient's"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/26/2026 - 04:31 PM Accepted by SEC EDGAR 06/26/2026 - 04:31 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Koppikar Utpal

(Last) (First) (Middle)

C/O C4 THERAPEUTICS, INC.

490 ARSENAL WAY #120

(Street)

WATERTOWN MASSACHUSETTS 02472

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
C4 Therapeutics, Inc. [ CCCC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$4.25	06/24/2026		A		62,000		(1)	06/23/2036	Common Stock	62,000	$0	62,000	D

Explanation of Responses:

1. This option shall vest and become exercisable in full upon the earlier to occur of (i) June 24, 2027 and (ii) the next annual meeting of the Issuer's stockholders, subject to the recipient's continued service as a member of the Board on such date.

Remarks:

	/s/ Shagha Russell, Attorney-in-Fact	06/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did C4 Therapeutics (CCCC) director Utpal Koppikar report on this Form 4?

Director Utpal Koppikar reported receiving a grant of stock options for 62,000 shares of C4 Therapeutics common stock. These options are a compensation award, not an open-market purchase, and give him the right to buy shares at a fixed exercise price in the future.

How many C4 Therapeutics (CCCC) shares are covered by the new stock options?

The new stock option grant covers 62,000 shares of C4 Therapeutics common stock. All 62,000 options were acquired in a single award, and his total options following the transaction are 62,000, reflecting this new grant as his reported derivative holding.

What is the exercise price and expiration date of the C4 Therapeutics options?

The options have an exercise price of $4.25 per share and expire on June 23, 2036. This means he can choose to buy shares at $4.25 any time after vesting and before expiration, subject to the option agreement’s terms.

When do Utpal Koppikar’s C4 Therapeutics stock options vest?

The options will vest and become exercisable in full on the earlier of June 24, 2027 or the next annual stockholder meeting. Vesting is contingent on his continued service as a Board member through that vesting date, according to the footnote disclosure.

Is this C4 Therapeutics Form 4 a stock purchase or a compensation grant?

This Form 4 reflects a compensation-related stock option grant, not an open-market stock purchase. The transaction code is “A” for grant or award, and the price per option is reported as $0.00, consistent with an option award from the company.